Composition for the preventive or curative treatment of liver disorders

Bacterial strains belonging to the species B. bifidum selected from the group comprising, or consisting of:

• (iii) Bifidobacterium bifidum BB07, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7 Apr. 2017 and having the deposit no. 32480;
• and
• (iv) Bifidobacterium bifidum BB08, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7 Apr. 2017 and having the deposit no. 32481.

Bacterial strains belonging to the species B. longum selected from the group comprising, or consisting of:

• (v) Bifidobacterium longum BL22, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7 Apr. 2017 and having the deposit no. 32482;
• and
• (vi) Bifidobacterium longum BL23, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7 Apr. 2017 and having the deposit no. 32483.

A composition (C) which comprises an effective amount of a mixture comprising, or consisting of, at least one bacterial strain belonging to at least one species selected from the group comprising or, alternatively, consisting of Bifidobacterium longum, Bifidobacterium adolescentis and Bifidobacterium bifidum, for use in the preventive and/or curative treatment of symptoms and/or pathologies deriving from, or connected to, metabolic syndrome, enlarged liver, non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH) in a subject, wherein said treatment comprises oral administration of said composition (C) to the subject.

A pharmaceutical preparation or medical device or food supplement comprising a composition (C) which comprises (i) an effective amount of a mixture comprising, or consisting of, at least one bacterial strain belonging to at least one species selected from the group comprising or, alternatively, consisting of Bifidobacterium longum, Bifidobacterium adolescentis and Bifidobacterium bifidum and (ii) at least one excipient suitable for pharmaceutical and/or food use.